However, because of the known complexity of STAT3 dysregulation, and because an association between PTEN status and response to STAT3 inhibition has not been shown, it would be premature to exclude such a significant proportion of patients with GBM from a clinical trial of a STAT3 inhibitor. Here, STAT3 is linked to glioblastoma.